Age | 6-12 years N = 583 | 13-18 years N = 239 | All patients N = 822 | U-test2 Chi2-test3 |
---|---|---|---|---|
Reason for starting OROS MPH, n (%)1 | ||||
N | 142 (100.00) | 82 (100.00) | 224 (100.00) | p < 0.0903 |
insufficient effectiveness | 92 (64.79) | 63 (76.83) | 155 (69.20) | |
adverse events | 5 (3.52) | 4 (4.88) | 9 (4.02) | |
combination of both | 45 (31.69) | 15 (18.29) | 60 (26.79) | |
Dose of OROS MPH | ||||
starting dose (mg/day) | 29.05 ± 11.71 | 37.58 ± 15.62 | 31.53 ± 13.52 | p < 0.0012 |
minimum, median, maximum | 18, 36, 72 | 18, 36, 108 | 18, 36, 108 | |
last visit | 32.82 ± 12.68 | 41.95 ± 15.07 | 35.47 ± 14.04 | p < 0.0012 |
minimum, median, maximum | 18, 36, 72 | 18, 36, 108 | 18, 36, 108 | |
Difference (mean ± SD) | 3.77 ± 9.03 | 4.37 ± 10.43 | 3.94 ± 9.46 | p = 0.5792 |
Wilcoxon p-value | < 0.0001 | < 0.0001 | < 0.0001 | |
Dose of OROS MPH (mg/day/kg BW) | N = 527 4 | N = 223 4 | N = 750 4 | |
starting dose (mg/day/kg BW) | 0.90 ± 0.41 | 0.73 ± 0.39 | 0.85 ± 0.41 | p < 0.0012 |
minimum, median, maximum | 0.30,0.82,3.13 | 0.20,0.66,2.77 | 0.20,0.78,3.13 | |
last visit | 1.03 ± 0.45 | 0.82 ± 0.37 | 0.97 ± 0.44 | p < 0.0012 |
minimum, median, maximum | 0.29,0.95,3.13 | 0.20,0.72,2.32 | 0.20,0.88,3.13 | |
Difference (mean ± SD) | 0.13 ± 0.32 | 0.08 ± 0.20 | 0.11 ± 0.29 | p = 0.6652 |
Wilcoxon p-value | < 0.0001 | < 0.0001 | < 0.0001 | |
Days of treatment with OROS MPH | 82.90 ± 30.32 | 87.36 ± 27.15 | 84.20 ± 29.49 | p = 0.0122 |
Days of observation | 85.97 ± 29.35 | 89.05 ± 26.10 | 86.87 ± 28.46 | p = 0.0462 |
Number (%) of patients with at least one additional application of IR MPH between study start and study end | ||||
yes | 180 (30.87) | 68 (28.45) | 248 (30.17) | p = 0.5463 |
no | 403 (69.13) | 171 (71.55) | 574 (69.83) |